Reuters - Novartis AG's blood cancer drug INC424 could rake in annual sales of $1 billion, the group's head of oncology told Reuters on Tuesday, in a boost to the Swiss drugmaker's cancer pipeline.
Source: http://us.rd.yahoo.com/dailynews/rss/diseases/*http://news.yahoo.com/s/nm/20110315/hl_nm/us_novartis_bloodcancer
cash for settlement social studies curriculum samples
